Shareholding disclosure

Cosmo Pharmaceuticals NV, Amsterdam

Declared position

9.5%

Threshold

Crossed downwards

Timeline

Published

22.10.2021

Transaction

19.10.2021

Transfer date

19.10.2021

Voting rights breakdown

Voting rights acquired5%

Voting rights sold9.5%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TALAL00017

Beneficial owner

Cosmo Pharmaceuticals NV, Amsterdam

Declared address

Cosmo Pharmaceuticals NV, Amsterdam

Purchase of own shares

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Cosmo Pharmaceuticals NV, Amsterdam

Cosmo N.V.22.10.2021TALAL00017

Disclosure summary

Cosmo Pharmaceuticals NV, Amsterdam disclosed a holding in Cosmo N.V. on the disposal side, published by SIX Exchange Regulation on 22.10.2021, at 9.5% of voting rights. Notice category: Single shareholder.

Disclosed position

9.5%

Voting rights sold

Voting rights acquired5%

Voting rights sold9.5%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Cosmo Pharmaceuticals NV, Amsterdam disclosed a holding in Cosmo N.V., published on 22.10.2021.

Publication date22.10.2021

Transaction date19.10.2021

Transfer date19.10.2021

Issuing companyCosmo N.V.

Beneficial ownerCosmo Pharmaceuticals NV, Amsterdam

Declared addressCosmo Pharmaceuticals NV, Amsterdam

CategorySingle shareholder

Voting rights acquired5%

Voting rights sold9.5%

Below threshold0%

ExchangeXSWX

Notification IDTALAL00017

Conditions

Purchase of own shares

Source: SIX Exchange Regulation · Publication date: 22.10.2021

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open